A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339Phase 3Recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 310 (estimated)
- Start date
- 18 Jun 2026
- Primary completion
- 15 Dec 2032 (estimated)
- Study completion
- 17 Aug 2037
- Last update posted
- 26 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Triple
- Arms
- 2
Interventions
- Calderasib Drug
- Durvalumab Biological
- Placebo to MK-1084 Other
Conditions and primary outcome
- Non-small Cell Lung Cancer
Primary outcome
Progression-Free Survival (PFS) (Up to approximately 6 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07554339.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07554339 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.